Partial
Partially Aligned
Patient Risk:
Low
Summary
Only a limited subset of label-related content is evaluated (suicidality/depression warning elements). The provided content includes unsupported/confounded claims about “registration in Spain,” and the evaluation does not include the AI response text to verify label alignment across relevant categories (e.g., dosing/administration, boxed warnings, drug interactions, adverse reactions details beyond the cross-reference).
Category Scores
Accurate Statements
The label includes contraindications for patients with Huntington’s disease who are suicidal or have untreated or inadequately treated depression (see Warnings and Precautions 5.1).
4 CONTRAINDICATIONS; cross-reference to 5.1
The label states AUSTEDO XR and AUSTEDO may increase the risk of suicidality in patients with Huntington’s disease and includes trial information on suicidal ideation (2% vs no placebo) and depression (4%).
5.1 Depression and Suicidality in Patients with Huntington’s Disease
The label recommends balancing risk of suicidality against need for treatment and observing all patients for new/worsening depression or suicidality, with consideration of discontinuation if not resolved.
5.1 Depression and Suicidality in Patients with Huntington’s Disease
The label instructs immediate evaluation for patients with Huntington’s disease who express suicidal ideation.
5.1 Depression and Suicidality in Patients with Huntington’s Disease
The label includes patient counseling that AUSTEDO XR and AUSTEDO may increase the risk of depression, worsening depression, and suicidality and instructs immediate reporting of symptoms to a healthcare provider (with citations to Contraindications 4 and Warnings/Precautions 5.1).
17 PATIENT COUNSELING INFORMATION
Unsupported Statements
Austedo (deutetrabenazine) registration in Spain cannot be confirmed from the information provided.
The provided FDA label excerpt does not contain information about Spanish authorization/registration status; this claim cannot be verified from the supplied FDA-specific labeling content.
To verify whether a medicine is authorized/registered for sale in Spain, Spanish drug authority records (such as AEMPS databases) or the product’s listing in official EU/Spain sources must be checked.
This is not supported by the supplied FDA-approved prescribing information content.
The evaluation indicates the AI-generated content aligns with FDA-approved labeling elements related to contraindications and the boxed-safety-relevant suicidality warning for Huntington’s disease.
The supplied excerpts do not include any boxed warning section text; therefore, whether a boxed warning is present or “boxed-safety-relevant” is not demonstrably supported by the provided label text.
Contradictions
Important Omissions
No explicit evaluation is provided for boxed warnings (if applicable), dosage and administration, drug interactions, or other safety sections beyond 5.1 and the cross-reference in 6 ADVERSE REACTIONS. This limits assessment of overall label alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only safety content evaluated (depression/suicidality risk in Huntington’s disease) is supported by the provided label excerpts; other categories are not assessed due to missing AI response text and incomplete label coverage.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Non-FDA claims about Spain registration are outside the scope of the FDA label provided, and the assertion about a “boxed” warning is not supported by the supplied label excerpts.
Suggested Improvement
Evaluate only statements grounded in the supplied FDA labeling text, remove/segregate Spain registration assertions, and avoid referencing boxed-warning status unless the boxed warning text is provided in the supplied materials.